Two reported mechanisms how PTEN loss promotes trastuzumab resistance are the transformation of Her-2 positive breast cancer into a triple negative subtype through induction of the epithelial-mesenchymal transition (EMT) [20] and the development of autophagy defects [21]. Here, ERBB2 is linked to breast cancer.